Medical Technology Media Alert: Vycor Medical, Inc.
(VYCO) Company's NovaVision's Vision Restoration Therapy Featured in Radio
Interview
Patient Shares Success Story
and How "It's the Only Option for Vision Therapy"
BOCA RATON, FL - June 4, 2015 (Investorideas.com
Newswire) - Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic
solutions issues a media alert for NovaVision, one of its core business units.
NovaVision was recently featured in radio interview with a patient discussing
its unique neurostimulation therapy.
Former patient Carole Urban discusses her
first-hand experience with Vision Restoration Therapy (VRT) on KSBT Radio FM
91.5 It's Your Health. Carole had had lost her sight as a result of brain
damage incurred from a motorcycle accident and has regained her life after
undertaking NovaVision's Vision Restoration Therapy (VRT).
Carole notes in the interview that she and her
sister researched her options and that NovaVision's Vision Restoration Therapy
was the only vision therapy they could find. Despite the skepticism of her
physician, she says her vision was restored to 91% as a result of using it for
six months.
Carole Urban was interviewed earlier this month on
WYPL 89.3 FM Memphis, TN "Eye On Vision" Radio Show, the show reaches
a large group of visually impaired listeners through the show's podcast. This
interview was picked by the producer following hearing about Carole's ability
to run again and pursue her hobbies since she got her vision back.
In April Carole had also been interviewed on
iHeartRadio and WLBY 1290 on the Ann Arbor's Business Talk Radio, "The
Lucy Ann Lance Radio Show". WLBY,"Ann Arbor's Talk Station carries
nationally syndicated programs such as The Mike Huckabee Show, Geraldo Rivera,
and John Bachelor.
NovaVision has the only commercially available, FDA
cleared therapy underpinned by 15 years of research and clinical studies for
the restoration of vision loss resulting from neurological brain damage of
which Stroke and TBI are the most common causes.
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL,
Vycor Medical, Inc. ("Vycor") is a publicly traded company (VYCO)
dedicated to providing the medical community with innovative and superior
surgical and therapeutic solutions and has a growing portfolio of FDA cleared
medical solutions that are changing and improving lives every day. The Company
operates two business units: Vycor Medical and NovaVision, both of which adopt
a minimally or non-invasive approach. Both technologies have exceptional sales
growth potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating revenue.
Vycor Medical's ViewSite(TM) Surgical Access
Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable
devices that hold the potential for speedier, safer and more economical brain
surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical
site access, reduce patient risk, accelerate recovery and add tangible value to
the professional medical community. The company is ISO 13485:2003 compliant,
has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory
approvals for brain in Australia, Canada, China, Europe (EU - Class III), Korea
and Japan and is seeking or has partial regulatory approvals in Brazil, India,
Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS see VBAS
Video.
NovaVision develops and provides science-driven
neurostimulation therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision impairments. The
company's proprietary Visual Restoration Therapy(R) (VRT) platform is clinically
supported to improve lost vision resulting from stroke, traumatic brain injury
(“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared
medical device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any Physician. VRT
also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy
(NeET) in the EU, aimed at increasing visual sensitivity deep within the field
defect.
The Company has also developed a therapy called
NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to
VRT(TM). The two therapies address different visual disabilities each of which
results from neurologically-induced vision loss - a loss of visual field as
well as difficulty with eye movement, affecting the ability to integrate visual
information. VRT provides partial restoration of the patient’s lost visual
field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement
and re-train the patients’ ability to integrate visual information between the
left and right hand side. For an overview of NovaVision see NovaVision Video.
For the latest information on the company,
including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute
forward-looking statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. The words "forecast", "anticipate",
"estimate", "project", "intend",
"expect", "should", "believe", and similar
expressions are intended to identify forward-looking statements. These
forward-looking statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Vycor Medical's actual
results, performance (financial or operating) or achievements to differ from
the future results, performance (financial or operating) or achievements
expressed or implied by such forward-looking statements. The risks, uncertainties
and other factors are more fully discussed in Vycor Medical’s filings with the
U.S. Securities and Exchange Commission. All forward-looking statements
attributable to Vycor Medical herein are expressly qualified in their entirety
by the above-mentioned cautionary statement. Vycor Medical disclaims any
obligation to update forward-looking statements contained in this estimate,
except as may be required by law.
Vycor Medical, Inc. Contacts:
SOURCE: Vycor Medical, Inc.
Disclaimer/Disclosure: The Investorideas.com newswire is a third
party publisher of news as well as creates original content as a news source.
Original content created by investor ideas is protected by copyright laws other
than syndication rights. Investorideas is a news source on Google news and
global syndication partners. Our site does not make recommendations for
purchases or sale of stocks or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated by featured companies, news submissions and advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. Vycor Medical Inc. (VYCO):
June 2, 2015 – The company has retained Investor Ideas for PR, media and news
distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer: Effective
September 15 2008 - all BC investors should review all OTC and Pink sheet
listed companies for adherence in new disclosure filings and filing appropriate
documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
